Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1972 1
1973 3
1974 1
1976 1
1977 1
1979 1
1980 1
1981 1
1982 2
1984 1
1985 2
1986 1
1988 2
1990 1
1991 2
1993 1
1994 2
1996 1
1999 2
2000 1
2001 5
2003 3
2004 3
2005 3
2006 3
2007 4
2008 7
2009 4
2010 5
2011 12
2012 6
2013 16
2014 14
2015 20
2016 22
2017 15
2018 22
2019 31
2020 45
2021 44
2022 65
2023 71
2024 46

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

455 results

Results by year

Filters applied: . Clear all
Page 1
Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's Disease.
Peyrin-Biroulet L, Chapman JC, Colombel JF, Caprioli F, D'Haens G, Ferrante M, Schreiber S, Atreya R, Danese S, Lindsay JO, Bossuyt P, Siegmund B, Irving PM, Panaccione R, Cao Q, Neimark E, Wallace K, Anschutz T, Kligys K, Duan WR, Pivorunas V, Huang X, Berg S, Shu L, Dubinsky M; SEQUENCE Study Group. Peyrin-Biroulet L, et al. N Engl J Med. 2024 Jul 18;391(3):213-223. doi: 10.1056/NEJMoa2314585. N Engl J Med. 2024. PMID: 39018531 Clinical Trial.
A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE): a multicentre, open-label randomised controlled trial.
Noor NM, Lee JC, Bond S, Dowling F, Brezina B, Patel KV, Ahmad T, Banim PJ, Berrill JW, Cooney R, De La Revilla Negro J, de Silva S, Din S, Durai D, Gordon JN, Irving PM, Johnson M, Kent AJ, Kok KB, Moran GW, Mowat C, Patel P, Probert CS, Raine T, Saich R, Seward A, Sharpstone D, Smith MA, Subramanian S, Upponi SS, Wiles A, Williams HRT, van den Brink GR, Vermeire S, Jairath V, D'Haens GR, McKinney EF, Lyons PA, Lindsay JO, Kennedy NA, Smith KGC, Parkes M; PROFILE Study Group. Noor NM, et al. Among authors: din s. Lancet Gastroenterol Hepatol. 2024 May;9(5):415-427. doi: 10.1016/S2468-1253(24)00034-7. Epub 2024 Feb 22. Lancet Gastroenterol Hepatol. 2024. PMID: 38402895 Free PMC article. Clinical Trial.
A Roadmap for the Human Gut Cell Atlas.
Zilbauer M, James KR, Kaur M, Pott S, Li Z, Burger A, Thiagarajah JR, Burclaff J, Jahnsen FL, Perrone F, Ross AD, Matteoli G, Stakenborg N, Sujino T, Moor A, Bartolome-Casado R, Bækkevold ES, Zhou R, Xie B, Lau KS, Din S, Magness ST, Yao Q, Beyaz S, Arends M, Denadai-Souza A, Coburn LA, Gaublomme JT, Baldock R, Papatheodorou I, Ordovas-Montanes J, Boeckxstaens G, Hupalowska A, Teichmann SA, Regev A, Xavier RJ, Simmons A, Snyder MP, Wilson KT; Gut Cell Atlas Consortium; Human Cell Atlas Gut Biological Network Consortium. Zilbauer M, et al. Among authors: din s. Nat Rev Gastroenterol Hepatol. 2023 Sep;20(9):597-614. doi: 10.1038/s41575-023-00784-1. Epub 2023 May 31. Nat Rev Gastroenterol Hepatol. 2023. PMID: 37258747 Free PMC article. Review.
Exenatide once weekly over 2 years as a potential disease-modifying treatment for Parkinson's disease: protocol for a multicentre, randomised, double blind, parallel group, placebo controlled, phase 3 trial: The 'Exenatide-PD3' study.
Vijiaratnam N, Girges C, Auld G, Chau M, Maclagan K, King A, Skene S, Chowdhury K, Hibbert S, Morris H, Limousin P, Athauda D, Carroll CB, Hu MT, Silverdale M, Duncan GW, Chaudhuri R, Lo C, Del Din S, Yarnall AJ, Rochester L, Gibson R, Dickson J, Hunter R, Libri V, Foltynie T. Vijiaratnam N, et al. Among authors: del din s. BMJ Open. 2021 May 28;11(5):e047993. doi: 10.1136/bmjopen-2020-047993. BMJ Open. 2021. PMID: 34049922 Free PMC article.
Falls Risk in Relation to Activity Exposure in High-Risk Older Adults.
Del Din S, Galna B, Lord S, Nieuwboer A, Bekkers EMJ, Pelosin E, Avanzino L, Bloem BR, Olde Rikkert MGM, Nieuwhof F, Cereatti A, Della Croce U, Mirelman A, Hausdorff JM, Rochester L. Del Din S, et al. J Gerontol A Biol Sci Med Sci. 2020 May 22;75(6):1198-1205. doi: 10.1093/gerona/glaa007. J Gerontol A Biol Sci Med Sci. 2020. PMID: 31942969 Free PMC article. Clinical Trial.
Smartphone Sensors for Indoor Positioning.
Ashraf I, Park Y, Zikria YB, Din S. Ashraf I, et al. Among authors: din s. Sensors (Basel). 2023 Apr 7;23(8):3811. doi: 10.3390/s23083811. Sensors (Basel). 2023. PMID: 37112152 Free PMC article.
Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group. Electronic address: recoverytrial@ndph.ox.ac.uk; RECOVERY Collaborative Group. RECOVERY Collaborative Group. Electronic address: recoverytrial@ndph.ox.ac.uk, et al. Lancet. 2023 May 6;401(10387):1499-1507. doi: 10.1016/S0140-6736(23)00510-X. Epub 2023 Apr 13. Lancet. 2023. PMID: 37060915 Free PMC article. Clinical Trial.
Digital Mobility Measures: A Window into Real-World Severity and Progression of Parkinson's Disease.
Mirelman A, Volkov J, Salomon A, Gazit E, Nieuwboer A, Rochester L, Del Din S, Avanzino L, Pelosin E, Bloem BR, Della Croce U, Cereatti A, Thaler A, Roggen D, Mazza C, Shirvan J, Cedarbaum JM, Giladi N, Hausdorff JM. Mirelman A, et al. Among authors: del din s. Mov Disord. 2024 Feb;39(2):328-338. doi: 10.1002/mds.29689. Epub 2023 Dec 27. Mov Disord. 2024. PMID: 38151859
455 results